| Literature DB >> 32114672 |
Rikke Rosbjerg1,2, Dorte Gilså Hansen3, Robert Zachariae4, Inger Hoejris5, Thomas Lund6,7, Merete Labriola6,8.
Abstract
Purpose The aim of the present study was to examine the predictive value of Return to Work Self-efficacy (RTWSE) on Return to Work (RTW) among employees undergoing chemotherapy for cancer and to examine the relative contribution of RTWSE as predictor variable compared to personal, health-related, illness- and treatment-related and work-related factors. Methods A sample of 114 sickness absent employees with various cancers (age 18-62) included in the study on average 33 days after initiating chemotherapy were followed for 15 months. Data sources included patient questionnaires (RTWSE, depression, fatigue, performance status), sociodemographic factors (age, sex, job type, and perceived support from the workplace), patient records (type of cancer, treatment intention, number of treatment modalities, time since diagnosis and time since initiation of chemotherapy), and Danish national registries (RTW and education). Associations between RTWSE at baseline and weeks until full RTW during 15-months follow-up were analyzed using Cox proportional hazards regression. Results In the univariate analysis, high RTWSE was associated with shorter time to RTW (Hazard Ratio (HR) 1.84, 95% confidence interval (CI) 1.12-3.03). In the multivariate model, RTWSE failed to reach statistical significance (HR 1.12, 95% CI 0.62-2.02), whereas female sex (HR 0.30, 95% CI 0.15-0.60) and receiving palliative treatment (HR 0.15, 95% CI 0.05-0.44) were significantly associated with later RTW. Conclusion Compared to other factors of significance, RTWSE was not the strongest predictor of RTW when examined among employees undergoing chemotherapy for cancer. Before using the RTWSE questionnaire to identify employees with cancer at risk of late RTW, it is important to recognize that the predictive value of RTWSE may be different for employees on sick leave due to cancer than for other sickness absence populations.Entities:
Keywords: Cancer; Prediction; Return to work; Self-efficacy; Work ability
Year: 2020 PMID: 32114672 PMCID: PMC7716905 DOI: 10.1007/s10926-020-09882-2
Source DB: PubMed Journal: J Occup Rehabil ISSN: 1053-0487
Fig. 1Flow chart of inclusion
Baseline sociodemographic, health-related, illness- and treatment-related, and work-related characteristics of a population of 114 sickness absent employees initiating chemotherapy for cancer
| N | ||
|---|---|---|
| Age (years) (mean and SD, range) | 114 | 51 (7.47), 25–62 |
| Gender (n and %) | 114 | |
| Female | 87 (76) | |
| Man | 27 (24) | |
| Education level (n and %) | 112 | |
| None | 11 (10) | |
| Short | 44 (39) | |
| Medium | 42 (38) | |
| Long | 15 (13) | |
| Work type (n and %) | 112 | |
| Physical | 31 (28) | |
| Sedentary | 47 (42) | |
| Mixed | 34 (30) | |
| Perceived support from the work place (mean and SD) | 107 | 8.50 (2.38) |
| Type of cancer (n and %) | 114 | |
| Female reproductive system | 8 (7) | |
| Breast | 56 (49) | |
| Lung incl. mesotheliomas | 10 (9) | |
| Urological incl. male reproductive system | 5 (4) | |
| Upper gastrointestinal | 11 (10) | |
| Colorectal | 13 (12) | |
| Cerebral and the central nervous system | 5 (4) | |
| Other | 6 (5) | |
| Treatment intention (n and %) | 114 | |
| Curative | 8 (7) | |
| Adjuvant | 62 (54) | |
| Neo-adjuvant | 18 (16) | |
| Palliative | 26 (23) | |
| Treatment modalities (n and %) | 114 | |
| Chemotherapy | 90 (79) | |
| Chemotherapy and one additional treatment modality | 21 (18) | |
| Chemotherapy and two additional treatment modalities | 3 (3) | |
| Time since diagnosis (days) (medium and iqr, range) | 114 | 69.50 (49–94), 20–1132 |
| Time since initiation of chemotherapy (days) (mean and SD, range) | 114 | 33 (19.91), 0–84 |
| Return to work self-efficacy (n and %) | 114 | |
| Low RTWSE | 63 (55) | |
| High RTWSE | 51 (45) | |
| Depression (n and %) | 113 | |
| No depression | 80 (71) | |
| Mild depression | 24 (21) | |
| Moderate depression | 9 (8) | |
| Severe depression | 0 (0) | |
| Fatigue (mean and SD) | 113 | 19.03 (SD: 8.20) |
| Performance status (n and %) | 113 | |
| Level 0: Fully active, able to carry on all pre-disease performance without restriction | 26 (23) | |
| Level I: Restricted in strenuous activity but able to carry out work of a light nature | 67 (59) | |
| Level II: Capable of all self-care but unable to carry out any work activity | 17 (15) | |
| Level III: Capable of only limited self-care, in bed for more than 50% of the time | 3 (3) | |
| Level IV: Cannot carry out any self-care, totally confined to bed or chair | 0 (0) |
Frequency, percentage and range, mean and standard deviation or median and interquartile range
RTWSE return to work self-efficacy, SD standard deviation, Iqr interquartile range
Fig. 2Aalen–Johansen cumulative incidence curves of full return to work for the low RTWSE group and the high RTWSE group. RTWSE return to work self-efficacy, RTW return to work, CI confidence interval
Bivariate associations between sociodemographic, health-related, illness- and treatment-related and work-related characteristics at baseline and weeks until full RTW during 15 months of follow-up in a population of 114 sickness absent employees initiating chemotherapy for cancer
| Variable | N | HR | 95% CI | P-value |
|---|---|---|---|---|
| RTWSE | 114 | 1.84 | 1.12–3.03 | 0.016* |
| Gender | ||||
| Men | 27 | 1 | – | – |
| Women | 87 | 0.58 | 0.32–1.02 | 0.059* |
| Age (years) | 114 | 1.01 | 0.98–1.05 | 0.484 |
| Educational level | ||||
| None | 11 | 1 | – | – |
| Short | 44 | 1.20 | 0.50–2.92 | 0.680 |
| Medium | 42 | 0.76 | 0.31–1.89 | 0.556 |
| Long | 15 | 1.09 | 0.39–3.06 | 0.873 |
| Work type | ||||
| Sedentary | 47 | 1 | – | – |
| Physical/mixed | 65 | 1.33 | 0.80–2.23 | 0.274 |
| Perceived support from work place (scale score) | 107 | 1.14 | 0.99–1.30 | 0.061* |
| Type of cancer | ||||
| Breast | 56 | 1 | – | – |
| Other | 58 | 1.28 | 0.78–2.12 | 0.326 |
| Treatment intention | ||||
| Curative, adjuvant, neo-adjuvant | 26 | 1 | – | – |
| Palliative | 88 | 0.31 | 0.13–0.78 | 0.013* |
| Treatment modalities | ||||
| Chemotherapy and no additional treatments | 90 | 1 | – | – |
| Chemotherapy + 1 or 2 additional treatments | 24 | 1.22 | 0.68–2.22 | 0.506 |
| Time since chemotherapy initiation (days) | 114 | 1.00 | 0.99–1.02 | 0.567 |
| Time since diagnosis (days) | 114 | 1.00 | 0.99–1.00 | 0.273 |
| Depression | ||||
| No depression | 80 | 1 | – | – |
| Symptoms of depression | 33 | 0.58 | 0.32–1.07 | 0.082* |
| Fatigue (sum score) | 113 | 1.00 | 0.97–1.03 | 0.985 |
| Performance status | ||||
| Fully active without restrictions (Level 0) | 26 | 1 | – | – |
| Restricted in some way (level ≥ I) | 87 | 0.85 | 0.48–1.51 | 0.584 |
Hazards ratios, confidence intervals and p-values of the bivariate Cox proportional hazards regression analyses
HR hazard ratio, CI confidence interval, RTWSE return to work self-efficacy
*Significant at p < 0.20
Hazard ratios for returning to work during 15 months of follow-up associated with the baseline level of return to work self-efficacy in a population of 114 employees undergoing treatment for cancer, including the Hazard Ratios for the covariates (gender, treatment intension, depression, and perceived support form work place)
| Model 1 (unadjusted) (N = 114) | Model 2a (N = 114) | Model 3b (N = 114) | Model 4c (N = 107) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HR | 95% CI | p value | HR | 95% CI | p value | HR | 95% CI | p value | HR | 95% CI | p value | |
| Low return to work self-efficacy | 1 | 1 | 1 | 1 | ||||||||
| High return to work self-efficacy | 1.84 | 1.12–3.03 | 1.75 | 1.06–2.89 | 1.58 | 0.95–2.65 | 0.079 | 1.12 | 0.62–2.02 | 0.711 | ||
| Gender | ||||||||||||
| Male | 1 | – | – | 1 | – | 1 | ||||||
| Female | 0.63 | 0.36–1.13 | 0.124 | 0.36 | 0.19–0.68 | 0.30 | 0.15–0.60 | |||||
| Treatment intention | ||||||||||||
| Curative, adjuvant, neo-adjuvant | 1 | 1 | – | |||||||||
| Palliative | 0.20 | 0.07–0.52 | 0.15 | 0.05–0.44 | ||||||||
| Depression | ||||||||||||
| No sign of depression | 1 | |||||||||||
| Symptoms of depression | 0.89 | 0.46–1.74 | 0.742 | |||||||||
| Perceived support from the work place | ||||||||||||
| Scale score* | 1.13 | 0.98–1.30 | 0.085 | |||||||||
Hazards ratios, confidence intervals and p-values of the unadjusted and the multivariate cox proportional hazards regression models
HR Hazard Ratio, CI Confidence interval
aAdjusted for gender
bAdjusted for gender and treatment intention
cAdjusted for gender, treatment intention, depression, and perceived support from the work place
*Scale score with higher scores referring to higher levels of perceived support